Peptide lexicon
Survodutid
Dual agonist at the glucagon and GLP-1 receptors in clinical development (BI 456906).
| Substance class | Peptide |
|---|---|
| CAS number | 2805997-46-8 |
| Molecular formula | C₁₉₂H₂₈₉N₄₇O₆₁ |
| Molar mass | 4,232 g/mol |
| Synonyms | BI 456906, Glukagon/GLP-1-Dual-Agonist |
| PubChem | CID 171378821 |
Structure
Survodutide is a lipidated peptide derived from glucagon that also activates the GLP-1 receptor. The glucagon component is studied as a way to influence energy expenditure and liver metabolism.
State of research
Research covers energy expenditure, liver fat and body weight in preclinical models and in phase II and III trials.
Status
Survodutide has no marketing authorisation and is in clinical development.
Literature
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and ObesityDiabetes Care, 2024 · PMID 38843460 · DOI 10.2337/dci24-0003
- Emerging pharmacotherapies for obesity: A systematic reviewPharmacol Rev, 2025 · PMID 39952695 · DOI 10.1124/pharmrev.123.001045
- Therapeutic horizons in metabolic dysfunction-associated steatohepatitisJ Clin Invest, 2025 · PMID 40590228 · DOI 10.1172/JCI186425
- Weight management treatment in obesityMed Clin (Barc), 2025 · PMID 40865172 · DOI 10.1016/j.medcli.2025.107152
- Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysisHepatology, 2025 · PMID 39903735 · DOI 10.1097/HEP.0000000000001254
